TY - JOUR
T1 - Current Knowledge and Perspectives for Pharmacological Treatment in OSA
AU - Baillieul, Sébastien
AU - Tamisier, Renaud
AU - Eckert, Danny J.
AU - Pépin, Jean-Louis
PY - 2022/10
Y1 - 2022/10
N2 - Obstructive sleep apnoea (OSA) impacts approximatively one billion people globally,1, 2 and is associated with detrimental cardiovascular, metabolic, and neurocognitive consequences, as well as bothersome diurnal symptoms that adversely impact daytime function and work productivity.3 It is now acknowledged that OSA is a highly heterogeneous condition encompassing various endophenotypes, defined as the association of clinical manifestations of OSA (phenotypes) and their underlying pathophysiological traits (endotypes).4 Identification of these endophenotypes is a prerequisite for risk stratification and prognosis anticipation.
AB - Obstructive sleep apnoea (OSA) impacts approximatively one billion people globally,1, 2 and is associated with detrimental cardiovascular, metabolic, and neurocognitive consequences, as well as bothersome diurnal symptoms that adversely impact daytime function and work productivity.3 It is now acknowledged that OSA is a highly heterogeneous condition encompassing various endophenotypes, defined as the association of clinical manifestations of OSA (phenotypes) and their underlying pathophysiological traits (endotypes).4 Identification of these endophenotypes is a prerequisite for risk stratification and prognosis anticipation.
KW - Obstructive sleep apnoea (OSA)
KW - Pharmacological Treatment
KW - Editorial
UR - http://www.scopus.com/inward/record.url?scp=85144916881&partnerID=8YFLogxK
UR - http://purl.org/au-research/grants/NHMRC/1116942
UR - http://purl.org/au-research/grants/NHMRC/1196261
U2 - 10.1016/j.arbres.2021.12.013
DO - 10.1016/j.arbres.2021.12.013
M3 - Editorial
AN - SCOPUS:85144916881
SN - 0300-2896
VL - 58
SP - 681
EP - 684
JO - Archivos de Bronconeumologia
JF - Archivos de Bronconeumologia
IS - 10
ER -